Table 1.

Clinical trials about exosome biomarkers

Investigators or contacts	Start time	Tumour	Estimated or actual enrollment	Time perspective	Origin	Potential marker	NCT number
Yuhui Shen et al. [86]	2017	Osteosarcoma	40	Prospective	Blood	RNA	NCT03108677
Shonit Punwani et al. [87]	2015	Prostate Cancer	130	Prospective	Blood	HER	NCT02935816
Shu Zhang et al. [88]	2018	Pancreatic Cancer	30	Prospective	Blood	mRNA	NCT03821909
Hyun Koo et al. [89]	2020	Lung Cancer	470	Retrospective	Blood	Protein	NCT04529915
Olivier Bouché et al. [90]	2021	Colorectal Cancer	80	Cross-Sectional	Blood	Macromolecules, integrins, metallo proteases	NCT04394572
Lei Li et al. [91]	2018	Ovarian Cancer	160	Prospective	Blood	miRNA, lncRNA	NCT03738319
Alice HERVIEU et al [92].	2018	Sarcoma	30	Prospective	Blood	Concentration	NCT03800121
Lin Miao et al. [93]	2017	Cholangiocarcinoma	80	Prospective	Blood	ncRNAs	NCT03102268
Henri MONTAUDIE et al. [94]	2014	Melanoma	15	Prospective	Blood	Concentration, size	NCT02310451
Julie ABRAHAM et al. [95]	2019	Non-Hodgkin B-cell Lymphomas	90	Prospective	Blood	CD20, PDL-1	NCT03985696
Roger Tun et al. [96]	2014	Prostate Cancer	2000	Prospective	Urine	RNA gene signature	NCT02702856
Carl A Olsson et al. [97]	2020	Bladder Cancer	3000	Prospective	Urine	the expression profiles of the sncRNAs	NCT04155359
CHIH-YUAN WANG et al. [98]	2016	Thyroid Cancer	22	Prospective	Urine	Uncertain	NCT02862470
Nicolas MOTTET et al. [99]	2020	Clear Cell Renal Cell Carcinoma	100	Prospective	Urine	CD9+/CA9+ exosomes, CD9+/VGEFR2+ exosomes, CD9+/CD63+/CD81+/CA9+ exosomes,	NCT04053855
Roger Tun et al. [100]	2016	Prostate Cancer	532	Prospective	Urine	3-gene expression	NCT03031418
Andrew Cowan et al. [101]	2015	Oropharyngeal Squamous Cell Carcinoma	30	Prospective	Primary cell cultures	Protein Signature	NCT02147418